Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $32.0 million.

  • Enanta Pharmaceuticals' Accumulated Expenses fell 232.72% to $32.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $32.0 million, marking a year-over-year decrease of 232.72%. This contributed to the annual value of $30.7 million for FY2025, which is 1088.74% down from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Accumulated Expenses stood at $32.0 million, which was down 232.72% from $30.7 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Accumulated Expenses peaked at $36.7 million during Q2 2023, and registered a low of $15.2 million during Q4 2022.
  • Its 5-year average for Accumulated Expenses is $26.9 million, with a median of $29.2 million in 2025.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Accumulated Expenses tumbled by 4295.33% in 2022, and later surged by 14079.67% in 2023.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Accumulated Expenses stood at $26.6 million in 2021, then crashed by 42.95% to $15.2 million in 2022, then skyrocketed by 140.8% to $36.5 million in 2023, then decreased by 10.32% to $32.7 million in 2024, then fell by 2.33% to $32.0 million in 2025.
  • Its Accumulated Expenses was $32.0 million in Q4 2025, compared to $30.7 million in Q3 2025 and $27.8 million in Q2 2025.